{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"}],"units":"Participants"}],"description":"The modified Response Evaluation Criteria in Solid Tumors Criteria (RECIST 2004) will be used for target lesions and assessed by CT scans. Complete Response (CR) is the disappearance of target lesions; Partial Response (PR) is greater than or equal to 30% reduction in the total tumor measurement; Stable Disease (SD) is the absence of response or progression; and Progressive Disease (PD) is a 20% increase in the total tumor measurement over nadir value or the appearance of new lesions.","groups":[{"description":"Zometa (zoledronic acid) will be administered by infusion on Day 1 of a 3-week cycle followed by tumor assessment from CT and/or PET scans every 2 cycles. This will continue until progression of disease and/or intolerable toxicity.\n\nZometa: Zoledronic acid will be administered IV on the first day of a 21 day cycle at a concentration of 4 mg. The treatment will take about 30-60 minutes with the infusion lasting about 15 minutes.","id":"OG000","title":"Zometa"}],"paramType":"NUMBER","populationDescription":"Participants with advanced malignant pleural mesothelioma.","reportingStatus":"POSTED","timeFrame":"Baseline up to 28 months or until progressive disease or death","title":"Tumor Response Rate Following Zoledronic Acid (Zometa)","type":"PRIMARY","unitOfMeasure":"percentage of responders"}